NCT05188573View on ClinicalTrials.gov

EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients

NAUnknownINTERVENTIONAL
Enrollment

10,000

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

May 31, 2025

Conditions
Pancreatic Cancer
Interventions
DEVICE

Early detection pancreatic cancer test

Blood collection and pancreatic cancer early detection testing with return of results

DEVICE

Early detection pancreatic cancer test and MRI Imaging

Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging

Trial Locations (1)

92121

Bluestar Genomics, Inc., San Diego

Sponsors

Lead Sponsor

ClearNote Health
All Listed Sponsors
lead

ClearNote Health

INDUSTRY

NCT05188573 - EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients | Biotech Hunter | Biotech Hunter